Lars Bastholt

6PUBLICATIONS
29CO-AUTHORS
Predictive and prognostic markersMechanobiologyMedical mycologyCancer therapy (excl. chemotherapy and radiation therapy)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Aug 31, 2026
Five-year survival impact of adjuvant anti-PD-1 therapy in a nationwide cohort of stage III melanoma.

|Oct 19, 2025
Dabrafenib plus trametinib vs encorafenib plus binimetinib in BRAF-mutant metastatic melanoma: a real-world propensity score-matched survival analysis.

Yago Garitaonaindia, Shawez Khan, Rasmus Friis

|Apr 14, 2025
Cardiotoxicity in patients with metastatic melanoma treated with BRAF/MEK inhibitors: a real-world analysis of incidence, risk factors, and reversibility.

Jonas K Oddershede, Ida K Meklenborg, Lars Bastholt

|Feb 22, 2022
Selumetinib Plus Adjuvant Radioactive Iodine in Patients With High-Risk Differentiated Thyroid Cancer: A Phase III, Randomized, Placebo-Controlled Trial (ASTRA).

Alan L Ho, Marek Dedecjus, Lori J Wirth

|Sep 16, 2020
Improved Progression-Free Long-Term Survival of a Nation-Wide Patient Population with Metastatic Melanoma.

Anne Vest Soerensen, Eva Ellebaek, Lars Bastholt

|Apr 10, 2020
Patient-Reported Outcomes During Immunotherapy for Metastatic Melanoma: Mixed Methods Study of Patients' and Clinicians' Experiences.

Lærke K Tolstrup, Helle Pappot, Lars Bastholt

Pageof 1

Frequent Collaborators

4 joint publications

Henrik Schmidt

2 joint publications

Eva Ellebaek

2 joint publications

Marco Donia

2 joint publications

Inge Marie Svane